StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the stock.
NanoViricides Price Performance
Shares of NanoViricides stock opened at $1.10 on Tuesday. The stock has a market cap of $12.96 million, a price-to-earnings ratio of -1.36 and a beta of 0.67. The firm’s 50-day moving average is $1.21 and its 200 day moving average is $1.16. NanoViricides has a 1 year low of $1.00 and a 1 year high of $2.00.
NanoViricides (NYSE:NNVC – Get Free Report) last posted its earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01.
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Further Reading
- Five stocks we like better than NanoViricides
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Stocks Leading the U.S. Agriculture Comeback
- The How And Why of Investing in Oil Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Comparing and Trading High PE Ratio Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
